Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected
Executive Summary
Puma Biotech has proven to be the cat with nine lives after its HER2+ breast cancer treatment neratinib received a u-turn from CHMP, granting it a positive trend vote. But even if final marketing approval is granted this year, European prospects don’t necessarily follow.
You may also be interested in...
New Keytruda Combo Wins Funding In England For NSCLC
MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.
Pierre Fabre Boosts Oncology Offering In Europe With Puma Deal
Another major deal with a US biotech has seen France’s Pierre Fabre exclusively licensing Puma’s Nerlynx for development and commercialization in Europe.
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.